TY - JOUR
T1 - Short-and Long-Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria
AU - Wang, Shudan
AU - Spielman, Allan
AU - Ginsberg, Mindy
AU - Petri, Michelle
AU - Rovin, Brad H.
AU - Buyon, Jill
AU - Broder, Anna
N1 - Funding Information:
This research was supported by the National Center for Advancing Translational Science Einstein – Montefiore CTSA grant number KL2 TR002558 to S. Wang, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases grants K23 AR068441 to A. Broder and 1UC2AR081039-01 to J. Buyon, M. Petri, B.H. Rovin, and A. Broder.
Publisher Copyright:
© 2022 by the American Society of Nephrology.
PY - 2022/8
Y1 - 2022/8
N2 - Background and objectives Lupus nephritis remains a common cause of morbidity and mortality in systemic lupus erythematosus (SLE). Current guidelines recommend performing a kidney biopsy at a urine protein-creatinine ratio of ≥0.5 g/g. However, cross-sectional studies reported a high prevalence of active histologic lupus nephritis lesions, and even chronic irreversible scarring, in patients with low-grade proteinuria. This study was initiated to assess disease progression in patients with SLE and low-grade proteinuria to identify risk factors for progression to overt proteinuria suggestive of clinical lupus nephritis. Design, setting, participants, & measurements Patients with SLE who had an incident urinary protein-creatinine ratio of ≥0.2 and,0.5 g/g without known lupus nephritis were identified from the Einstein Rheumatic Disease Registry. Patients who developed a random urinary protein-creatinine ratio of ≥0.5 g/g with or without biopsy during the follow-up period were defined as “progressors.” Patients who progressed to a urinary protein-creatinine ratio of ≥0.5 g/g within 2 years of developing a urinary protein-creatinine ratio of ≥0.2 and,0.5 g/g were defined as “fast progressors,” a subgroup expected to benefit most from early biopsies and therapeutic interventions. Results Among 151 eligible patients with SLE and low-grade proteinuria at study entry, 76 (50%) progressed to a urinary protein-creatinine ratio of ≥0.5 g/g, of which 44 underwent a clinically indicated biopsy. The median (interquartile range) time from a urinary protein-creatinine ratio of ≥0.2 and,0.5 g/g to progression was 1.2 (0.3–3.0) years. Of the 20 biopsies performed in the first 2 years, 16 specimens showed active, treatable lupus nephritis. Low complement and shorter SLE duration at low-grade proteinuria onset were associated with progression to overt proteinuria across different analyses. Other associated factors included hypertension, diabetes mellitus, younger age, and the presence of hematuria. Conclusions In this longitudinal cohort of patients with SLE and low-grade proteinuria at study entry, over half progressed to a urinary protein-creatinine ratio of ≥0.5 g/g in a short time period.
AB - Background and objectives Lupus nephritis remains a common cause of morbidity and mortality in systemic lupus erythematosus (SLE). Current guidelines recommend performing a kidney biopsy at a urine protein-creatinine ratio of ≥0.5 g/g. However, cross-sectional studies reported a high prevalence of active histologic lupus nephritis lesions, and even chronic irreversible scarring, in patients with low-grade proteinuria. This study was initiated to assess disease progression in patients with SLE and low-grade proteinuria to identify risk factors for progression to overt proteinuria suggestive of clinical lupus nephritis. Design, setting, participants, & measurements Patients with SLE who had an incident urinary protein-creatinine ratio of ≥0.2 and,0.5 g/g without known lupus nephritis were identified from the Einstein Rheumatic Disease Registry. Patients who developed a random urinary protein-creatinine ratio of ≥0.5 g/g with or without biopsy during the follow-up period were defined as “progressors.” Patients who progressed to a urinary protein-creatinine ratio of ≥0.5 g/g within 2 years of developing a urinary protein-creatinine ratio of ≥0.2 and,0.5 g/g were defined as “fast progressors,” a subgroup expected to benefit most from early biopsies and therapeutic interventions. Results Among 151 eligible patients with SLE and low-grade proteinuria at study entry, 76 (50%) progressed to a urinary protein-creatinine ratio of ≥0.5 g/g, of which 44 underwent a clinically indicated biopsy. The median (interquartile range) time from a urinary protein-creatinine ratio of ≥0.2 and,0.5 g/g to progression was 1.2 (0.3–3.0) years. Of the 20 biopsies performed in the first 2 years, 16 specimens showed active, treatable lupus nephritis. Low complement and shorter SLE duration at low-grade proteinuria onset were associated with progression to overt proteinuria across different analyses. Other associated factors included hypertension, diabetes mellitus, younger age, and the presence of hematuria. Conclusions In this longitudinal cohort of patients with SLE and low-grade proteinuria at study entry, over half progressed to a urinary protein-creatinine ratio of ≥0.5 g/g in a short time period.
UR - http://www.scopus.com/inward/record.url?scp=85135598200&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135598200&partnerID=8YFLogxK
U2 - 10.2215/CJN.01280122
DO - 10.2215/CJN.01280122
M3 - Article
C2 - 35882508
AN - SCOPUS:85135598200
SN - 1555-9041
VL - 17
SP - 1150
EP - 1158
JO - Clinical Journal of the American Society of Nephrology
JF - Clinical Journal of the American Society of Nephrology
IS - 8
ER -